U.S. Food and Drug Administration Approves Acalabrutinib (CALQUENCE) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).